BioPharmaPT
← All reports

Johnson & Johnson — Lazcluze EMA EPAR public assessment report (EMEA/H/C/006074, 2025)

Johnson & Johnson · 2025 · EMA EPAR public assessment report · company profile →

Report summary

The EMA assessed Lazcluze (lazertinib) in combination with amivantamab for first-line treatment of advanced EGFR-mutated NSCLC. The CHMP issued a positive opinion for marketing authorization, despite not granting accelerated assessment. The report details the product's quality, manufacturing, and extensive non-clinical and clinical development. Lazertinib, a third-generation EGFR TKI, demonstrated potent anti-tumor activity and favorable pharmacokinetics. The pivotal MARIPOSA Phase 3 trial showed the combination therapy significantly improved progression-free survival (23.72 vs 16.59 months for osimertinib) and a favorable trend in overall survival. While common adverse events included rash and paronychia, venous thromboembolism (VTE) was identified as a significant, but manageable, risk. The overall benefit-risk balance was deemed positive.

Key findings — cited to the page

Grade 3+ Paronychia incidence in Amivantamab + Lazertinib (MARIPOSA)46 MARIPOSA · p.120
Grade 3+ Paronychia incidence in Osimertinib2 MARIPOSA · p.120
Grade 3 or higher AEs in Amivantamab158 · p.117
Grade 3+ Rash incidence in Amivantamab5 · p.120
Grade 3+ Rash incidence in Lazertinib7 · p.120
Grade 3+ Rash incidence in Osimertinib3 MARIPOSA · p.120
Grade 3 or higher AEs in Amivantamab + Lazertinib (MARIPOSA)316 MARIPOSA · p.117
Grade 3+ Pneumonia incidence in Lazertinib19 · p.120
Grade 3 or higher AEs in Lazertinib233 · p.117
Grade 3 or higher AEs in Osimertinib183 MARIPOSA · p.117
Grade 3+ Rash incidence in Amivantamab + Lazertinib (MARIPOSA)65 MARIPOSA · p.120
Grade 3+ Paronychia incidence in Lazertinib4 · p.120

Source: Johnson & Johnson · License: EMA - reuse permitted with acknowledgement. Summary and findings are extracted from the published document; every figure cites its page. Informational only — not investment advice. Explore the Oncology library →

Johnson & Johnson — Lazcluze EMA EPAR public assessment report (EMEA/H/C/006074, 2025) — Summary & Key Findings | BioPharmaPT